NCT05944783View on ClinicalTrials.gov

Bioequivalence Studies of Dasatinib 100 Mg

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 20, 2025

Study Completion Date

April 30, 2026

Conditions

Myeloma Multiple

Interventions

DRUG

Dasatinib 100 MG

single dose of 100 mg Dasatinib tablets

Trial Locations (1)

Unknown

CAIMED, Chía

All Listed Sponsors

lead

Centro de Atencion e Investigacion Medica

NETWORK